Mithra obtains crucial additional Estelle® patent in Japan

  • Estelle®, Mithra’s oral contraceptive product candidate, has been granted a key patent for the dysmenorrhea indication in Japan, a four times larger market than the contraceptive one.
  • Important milestone for the commercialization of Estelle® by Fuji Pharma in Japan and ASEAN, representing a total attractively priced market of EUR 400 million annual sales.
  • Thanks to a solid Intellectual Property strategy, Estelle® will be protected from any generic competitor on the Japanese market until 2037 with a potential patent term extension of a maximum of 5 years.

Liege, Belgium, 08 August 2019 – 7 :30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has received an additional patent for Estelle® in Japan in the dysmenorrhea indication. Estelle® is Mithra’s combined oral contraceptive (COC) candidate, composed of 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP).